Shots:
The US FDA has received the resubmitted NDA for rivoceranib + camrelizumab for the 1L systemic treatment option for unresectable or metastatic hepatocellular carcinoma (uHCC)
Following an FDA Complete Response Letter in Jul 2026 for its Jan NDA submission, Elevar Therapeutics resubmitted the NDA on October 9, 2026, after working with the FDA and…
